Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells-Reference-Cited by-同舟云学术

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

Published:2011-12 Issue:12 Volume:2 Page:e243-e243
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Michaelis M,Rothweiler F,Barth S,Cinatl J,van Rikxoort M,Löschmann N,Voges Y,Breitling R,von Deimling A,Rödel F,Weber K,Fehse B,Mack E,Stiewe T,Doerr H W,Speidel D,Cinatl J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/cddis2011129.pdf

Reference40 articles.

1. Brown CJ, Cheok CF, Verma CS, Lane DP . Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 2011; 32: 53–62.

2. Vassilev LT . MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13: 23–31.

3. Verma R, Rigatti MJ, Belinsky GS, Godman CA, Giardina C . DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 2010; 79: 565–574.

4. Valentine JM, Kumar S, Moumen A . A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer 2011; 11: 79.

5. Shen H, Moran DM, Maki CG . Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res 2008; 68: 8260–8268.

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDM2 inhibitors in cancer immunotherapy: Current status and perspective;Genes & Diseases;2024-11

2. BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition;Apoptosis;2024-09-02

3. Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect;Cancers;2024-04-05

4. New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics;Biomedicines;2024-02-29

5. Kinome‐Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma;Advanced Science;2024-02-14